{"entity":{"id":"alentis-therapeutics","kind":"company","name":"Alentis Therapeutics","aka":[],"tldr":"Alentis Therapeutics targets Claudin-1, a protein exposed on squamous cancers and scarred organs, with antibodies that either carry a cancer-killing drug or block disease signalling. Its first cancer medicine entered human trials in 2025.","summary":"Alentis Therapeutics is a clinical-stage Basel biotech focused on Claudin-1 (CLDN1), a tight-junction protein that becomes exposed on tumour cells and in fibrotic tissue. Its oncology pipeline comprises ALE.P02, a CLDN1-directed antibody-drug conjugate with a tubulin inhibitor payload for advanced or metastatic CLDN1-positive squamous solid tumours (FDA IND clearance October 2024, Fast Track designation November 2024, phase 1/2 trial planned from Q1 2025), and ALE.P03, a CLDN1 ADC with a topoisomerase 1 inhibitor payload entering first-in-human studies in 2025. The monoclonal antibody lixudebart (ALE.F02) is in development for organ fibrosis, with topline results in ANCA-associated glomerulonephritis and advanced liver fibrosis reported in January 2025. In November 2024 Alentis raised an oversubscribed USD 181.4 million Series D led by OrbiMed with co-leads Novo Holdings and Jeito Capital. Mark Pruzanski was appointed CEO in October 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://alentis.ch/"},{"label":"Series D press release","url":"https://alentis.ch/alentis-therapeutics-raises-181-4-million-in-an-oversubscribed-series-d-financing-to-advance-the-clinical-development-of-anti-claudin-1-adcs-in-solid-tumors/"},{"label":"News","url":"https://alentis.ch/news/"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc","monoclonal-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07169734","nct06747585"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Earlier rounds (Series A to C) not fetched and omitted."],"hq":"Basel","country":"CH","companyType":"biotech","website":"https://alentis.ch/","stage":"growth","investors":["orbimed","novo-holdings","jeito-capital","frazier-life-sciences","ra-capital","bpifrance"],"funding":[{"round":"Series D","year":2024,"amountUsd":181400000,"source":"https://alentis.ch/alentis-therapeutics-raises-181-4-million-in-an-oversubscribed-series-d-financing-to-advance-the-clinical-development-of-anti-claudin-1-adcs-in-solid-tumors/"}]},"route":"/companies/alentis-therapeutics/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"trial":[{"id":"nct06747585","kind":"trial","name":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","route":"/trials/nct06747585/"},{"id":"nct07169734","kind":"trial","name":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","route":"/trials/nct07169734/"}],"company":[{"id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/"},{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/"},{"id":"jeito-capital","kind":"company","name":"Jeito Capital","route":"/companies/jeito-capital/"},{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/"},{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"}]}}